ArticleScience advances2020
Suprachoroidal gene transfer with nonviral nanoparticles.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- Gene therapy induces pigmentation in induced pluripotent stem cell-derived retinal pigment epithelium of OCA1A patients and albino rat eye.Molecular therapy. Advances · 2026Article
- Anatomically Guided Non-Viral CRISPR/Cas9 Delivery in the Eye: Overcoming Barriers for Precision Gene Therapy.Pharmaceutics · 2026Review
- Suprachoroidal injection in the treatment of diabetic macular edema: mechanisms, clinical advances, and future perspectives.Frontiers in medicine · 2026Review
- Custom-Made Injector for Suprachoroidal Ocular Delivery: Effect of Intraocular Pressure, Volume, and Location on the Distribution of Aqueous Solutions in Rabbits.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2025Article
- Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans.Brain sciences · 2025Review
- Surgical Approaches to Retinal Gene Therapy: 2025 Update.Bioengineering (Basel, Switzerland) · 2025Review
- Review
- Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases.American journal of ophthalmology · 2025Review
- Advances in locally administered nucleic acid therapeutics.Bioactive materials · 2025Review
- Genetic engineering and the eye.Eye (London, England) · 2025Review
- Role of miRNA in adult ocular tumorigenesis.Frontiers in molecular biosciences · 2025Review
- What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Strategies for non-viral vectors targeting organs beyond the liver.Nature nanotechnology · 2024Review
- Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes.Science advances · 2024Article
- Immunology of Retinitis Pigmentosa and Gene Therapy-Associated Uveitis.Cold Spring Harbor perspectives in medicine · 2024Review
- How Advanced are Nanocarriers for Effective Subretinal Injection?International journal of nanomedicine · 2024Review
- Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina.Nature communications · 2023Article
- Updates on Emerging Interventions for Autosomal RecessiveJournal of clinical medicine · 2023Review
- Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates.Translational vision science & technology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Subretinal injections of viral vectors provide great benefits but have limited cargo capacity; they induce innate and adaptive immune responses, which may cause damage and preclude repeated injections; and they pose administration risks. As a new biotechnology, suprachoroidal injections of biodegradable nanoparticles (NPs) containing a reporter plasmid induce reporter expression in rat photoreceptors and RPE throughout the entire eye and maintain expression for at least 8 months. Multiple injections markedly increase expression. Suprachoroidal injection of NPs containing a VEGF expression plasmid caused severe subretinal neovascularization progressing to subretinal fibrosis, similar to what occurs in untreated patients with neovascular age-related macular degeneration, providing a new model and proof of concept for level and duration of expression. Suprachoroidal injection of NPs containing a VEGF-binding protein expression plasmid significantly suppressed VEGF-induced vascular leakage and neovascularization demonstrating therapeutic potential. These data suggest that nonviral NP suprachoroidal gene transfer may provide a noninvasive, repeatable alternative to subretinal injection of viral vectors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.